Background: Mometasone furoate/formoterol (MF/F) combination therapy is a new treatment recently approved by the US Food and Drug Administration for the treatment of persistent asthma and currently under regulatory review by Canadian authorities. We report findings from a noninferiority study that compared effects of MF/F and fluticasone propionate/salmeterol (FP/S) combination therapies on pulmonary function and onset of action in subjects with persistent asthma. Methods: This randomized, active-controlled, multicenter, noninferiority trial enrolled subjects (aged $12 years) previously treated with medium-dose inhaled corticosteroid alone or combined with a long-acting b 2 -agonist. Following a 2-to 4-week run-in treatment period with MF administered via a metered-dose inhaler (MDI) 200 mg twice daily (BID), eligible subjects were randomized to MF/F-MDI 200/10 mg BID or FP/S administered via a dry powder inhaler (DPI) 250/50 mg BID for 12 weeks. The primary endpoint of this trial was change from baseline in area under the curve (AUC) in forced expiratory volume in 1 second (FEV 1 ) measured serially for 0 to 12 hours postdose (FEV 1 AUC 0212h ). Key secondary endpoints included onset of action, defined as change from baseline in FEV 1 at 5 minutes postdose on day 1. Results: 722 subjects were randomized to MF/F-MDI (n ¼ 371) or FP/S-DPI (n ¼ 351). The trial's primary endpoint was met, demonstrating that MF/F administered via an MDI was noninferior to FP/S administered via a DPI in the patient population investigated. Mean FEV 1 AUC 0212h at endpoint for MF/F-MDI and FP/S-DPI was 3.43 versus 3.24 L · h, respectively (95%, CI, 20.40 to 0.76). Analysis of onset-of-action characteristics revealed that MF/ F's effect on lung function occurred significantly faster than the effect observed with FP/S-DPI. MF/F-MDI was associated with a 200-mL mean increase from baseline in FEV 1 at 5 minutes postdose (first scheduled measurement) on the first day of treatment vs a 90-mL increase for FP/S-DPI (P , 0.001).
Conclusions: This trial demonstrated that MF/F 200/10 mg BID administered via an MDI was noninferior to FP/S 250/50 mg BID administered via a DPI in its effect to improve lung function as measured by FEV1 AUC0-12h. However, the onset of action for this effect was significantly faster with MF/F-MDI than with FP/S-DPI. Background: Multiple strengths of mometasone furoate/formoterol (MF/F) metered-dose inhaler combination therapy have been investigated as new treatments for asthma. We report efficacy/safety findings from an MF/F study in subjects with severe asthma previously uncontrolled on high-dose inhaled corticosteroids (ICS) with or without a long-acting ß 2 -agonist (LABA). Methods: This was a 3-month, randomized, double-blind, parallel-group, multicenter study with a 2-to 3-week open-label run-in period during which subjects received mometasone furoate (MF) 400 mg twice daily (BID). Subjects ($12 years) were randomized to MF/F 200/10 mg BID, MF/F 400/10 mg BID, or MF 400 mg BID. The primary endpoint was the area under the curve (AUC) of the change in serial (0212 hours) forced expiratory volume in 1 second (FEV 1 ) for MF/F 400/10 mg vs MF 400 mg from baseline to week 12. Adverse events (AEs) and other clinical safety measures were recorded. Results: 728 subjects were randomized (mean: age, 47.9 years; asthma duration, 14.0 years; FEV 1 % predicted, 66.3; reversibility, 22.9%; Asthma Control Questionnaire score, 1.93). Improvements in mean changes from baseline in FEV 1 AUC 0212h at week 12 were: MF/F 200/10 mg ¼ 3.59 L · h; MF/F 400/10 mg ¼ 4.19 L · h; MF 400 mg ¼ 2.04 L · h, with both MF/F doses significantly better than MF (P , 0.001). These FEV 1 AUC 0-12h values with MF/F 200/10 mg, MF/F 400/10 mg, and MF 400 mg correspond to average hourly increases of 0.30, 0.35, and 0.17 L, respectively. MF/F was associated with a rapid (,5 minutes) and sustained improvement in lung function. The percentages of subjects experiencing an asthma deterioration (ie, severe asthma exacerbation) were 12.4% (MF/F 200/10 mg), 12.2% (MF/F 400/10 mg), and 18.3% (MF 400 mg). There were no notable differences in AEs between the groups. Conclusions: Both the 200/10 mg BID and 400/10 mg BID doses of MF/F combination therapy led to significantly greater improvements in lung function compared with 400 mg BID MF monotherapy in subjects with severe asthma previously treated with an ICS alone or in combination with LABA. Background: Asthmatics often report asthma-related nocturnal awakenings. These sleep interruptions may have a significant impact on patients' quality of life. We characterized the effect of mometasone furoate/formoterol (MF/F) administered via pressured metered-dose inhaler on incidence of nocturnal awakenings requiring short-acting b 2 -agonists (SABAs). Methods: MF/F's effect on nocturnal awakenings requiring SABA was characterized across 3 phase III efficacy trials (baseline ¼ number of nights with awakenings in week before first dose; endpoint ¼ number of nights/wk with awakenings averaged across the 26-week treatment period). Subjects were asthmatics previously treated with low-(n¼746), medium-(n¼781) or highdose (n¼728) inhaled corticosteroids at various doses. Subjects in the MF/F 100/10 mg BID study were randomized to 26 weeks of twice-daily (BID) treatment with MF/F 100/10 mg, MF 100 mg, F 10 mg, or placebo; subjects in the MF/F 200/10 mg BID study to 26 weeks of BID treatment with MF/F 200/ 10 mg, MF 200 mg, F 10 mg, or placebo; and subjects in the MF/F 400/10 mg BID study to 12 weeks of BID treatment with MF/F 400/10 mg, MF/F 200/10 mg, or MF 400 mg. All treatments were delivered via a metered dose inhaler. Results: Baseline awakenings ranged from 0.84-1.05, 1.05-1.26, and 1.33-1.61 nights/wk in the MF/F 100/10 mg BID, MF/F 200/10 mg BID, and MF/F 400/10 mg BID studies, respectively. In the MF/F 100/10 mg BID study, nocturnal awakenings were reduced by MF/F ¼ -0.42, MF ¼ -0.21, F ¼ -0.21, and placebo ¼ 0.14 nights/wk; corresponding changes in the MF/F 200/10 mg BID study were -0.56, -0.35, 10.07 and 0.00 nights/wk, respectively. In each of these placebo-controlled studies, MF/F was superior to placebo (P , .001) and F (P #.035); MF was also superior to F and placebo. In the MF/F 400/10 mg BID study, awakenings were reduced by -0.70, -0.70 and -0.35 nights/wk by MF/F 200/10 mg, MF/F 400/10 mg, and MF 400 mg, respectively; both MF/F treatments were superior to MF (P #0.006). Conclusions: These results provide evidence that validates the role of MF/F in reducing nocturnal asthma symptoms in patients with moderate to severe persistent asthma and supports the efficacy of MF/F compared with that of placebo and F. Background: A major goal of asthma treatment is to improve patients' health-related quality of life (QoL). Mometasone furoate/formoterol (MF/F) combination therapy was recently approved for the treatment of persistent asthma. The objective of this analysis was to examine the effect of MF/F on health-related QoL at the approved doses. Methods: Data from 2 phase III studies investigating the effects of MF/F 200/ 10 mg (study P04334) and MF/F 400/10 mg (study P04431) were included. All subjects were $12 yeara and not well controlled on medium dose (P04334) or high-dose (P04431) inhaled corticosteroid (ICS). After 2 to 3 weeks of run-in on twice-daily (BID) MF 200 mg (P04334) or 400 mg (P04431), subjects were randomized to 26 weeks of BID MF/F 200/10 mg, MF 200 mg, F 10 mg, or placebo (PBO) in P04334; or 12 weeks of BID MF/F 200/10 mg, MF/F 400/10 mg, or MF 400 mg in P04431. The Asthma Quality of Life Questionnaire with Standardized Activities (AQLQ [S]), consisting of 4 domains (Symptoms, Activity Limitation, Emotional Function, and Environmental Stimuli), was used to assess QoL. AQLQ(S) score changes from baseline were assessed; a difference $0.5 was considered clinically meaningful. Study protocols were approved by IRBs; written informed consent was provided by all subjects or a parent/guardian. Results: In P04334 (n ¼ 781), subjects receiving MF/F 200/10mg experienced significant improvements in total score (13.1%) and the 4 domain scores of the AQLQ (S) at endpoint vs those receiving PBO (P # 0.005) or F 10 mg (P # 0.024). Clinically meaningful improvements in total AQLQ (S) from baseline to week 26 were observed in patients receiving MF/F 200/ 10 mg (0.61). In P04431 (n ¼ 728), subjects receiving MF/F 200/10 mg experienced significant improvements in total score (12.8%) and the Symptoms and Activity Limitation domain scores of the AQLQ (S) at endpoint vs those who received MF 400 mg (P # 0.017). Clinically meaningful improvements in total AQLQ (S) from baseline to week 12 occurred in patients receiving MF/F 200/10 mg (0.61), MF/F 400/10 mg (0.51), or MF 400 mg (0.5). Conclusions: Patients with persistent asthma receiving MF/F had statistically significant, clinically meaningful improvements in QoL in 2 phase III studies. These data suggest that MF/F combination therapy improves the healthrelated QoL of patients with persistent asthma who are inadequately controlled on medium-or high-dose ICS. Background: Asthma is a variable disease. Optimal control in clinical practice often requires the use of therapy at varying doses. Availability of treatments at multiple strengths is therefore essential. These are results from a 6-month trial of combined mometasone furoate/formoterol (MF/F) 100/10 mg administered via a metered-dose inhaler (MDI) as treatment for asthma deterioration (ie, severe asthma exacerbation) and bronchoconstriction in asthmatics previously treated with low-dose inhaled corticosteroids (ICS). Methods: In a randomized, multicenter, double-blind, placebo-controlled study in asthma subjects ($12 years) on ICS with/without a long-acting b 2 -agonist (LABA), subjects were assigned to 2 to 3 weeks of open-label MF 100 twice daily (BID), followed by 26 weeks of MF/F 100/10 mg, MF 100 F 10 or placebo (all BID). Co-primary endpoints were time to first asthma deterioration across the 26-week treatment period (MF/F versus F) and change from baseline to week 12 in serial (0212 hours) forced expiratory volume in 1 second (FEV 1 ) (MF/F vs MF). Adverse events (AEs) were monitored. Results: 746 subjects (mean: age ¼ 38.3 years, asthma duration ¼ 14.77 years, FEV 1 % predicted ¼ 75.08, reversibility ¼ 18.69%, Asthma Control
